KRAS and lung adenocarcinoma: Given the relevance of the RAF-MEK-ERK pathway in KRAS-driven lung cancer3, particularly in the most frequently diagnosed subtype, lung adenocarcinoma (LUAD), combinations of MEK1/2 inhibitors (MEKi) with targeted agents to proximal elements of the KRAS signaling network have been reported4–12.